Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 37

1.

Modelling gastric emptying: a pharmacokinetic model simultaneously describing distribution of losartan and its active metabolite EXP-3174.

Karatza E, Karalis V.

Basic Clin Pharmacol Toxicol. 2019 Sep 12. doi: 10.1111/bcpt.13321. [Epub ahead of print]

PMID:
31514255
2.

In Vivo Evaluation of the Anti-Inflammatory Activity of Electrospun Micro/Nanofibrous Patches Loaded with Pinus halepensis Bark Extract on Hairless Mice Skin.

Kotroni E, Simirioti E, Kikionis S, Sfiniadakis I, Siamidi A, Karalis V, Vitsos A, Vlachou M, Ioannou E, Roussis V, Rallis M.

Materials (Basel). 2019 Aug 15;12(16). pii: E2596. doi: 10.3390/ma12162596.

3.

Hematocrit effect on dried blood spots in adults: a computational study and theoretical considerations.

Daousani C, Karalis V, Malenović A, Dotsikas Y.

Scand J Clin Lab Invest. 2019 Sep;79(5):325-333. doi: 10.1080/00365513.2019.1622033. Epub 2019 Jun 1.

PMID:
31154908
4.

Laparoscopic total extraperitoneal inguinal hernia repair: Retrospective study on prosthetic materials, postoperative management, and quality of life.

Georgiou E, Schoina E, Markantonis SL, Karalis V, Athanasopoulos PG, Chrysoheris P, Antonakopoulos F, Konstantinidis K.

Medicine (Baltimore). 2018 Dec;97(52):e13974. doi: 10.1097/MD.0000000000013974.

5.

On the population pharmacokinetics and the enterohepatic recirculation of total ezetimibe.

Soulele K, Karalis V.

Xenobiotica. 2019 Apr;49(4):446-456. doi: 10.1080/00498254.2018.1463117. Epub 2018 Apr 27.

PMID:
29629619
6.

In vitro Controlled Release of two new Tuberculocidal Adamantane Aminoethers from Solid Pharmaceutical Formulations (II).

Vlachou M, Siamidi A, Spaneas D, Lentzos D, Ladia P, Anastasiou K, Papanastasiou I, Foscolos AS, Georgiadis MO, Karalis V, Kellici T, Mavromoustakos T.

Drug Res (Stuttg). 2017 Nov;67(11):653-660. doi: 10.1055/s-0043-114012. Epub 2017 Jul 19.

PMID:
28724167
7.

In vitro Controlled Release from Solid Pharmaceutical Formulations of two new Adamantane Aminoethers with Antitubercular Activity (I).

Vlachou M, Siamidi A, Diamantidi E, Iliopoulou A, Papanastasiou I, Ioannidou V, Kourbeli V, Foscolos AS, Vocat A, Cole ST, Karalis V, Kellici T, Mavromoustakos T.

Drug Res (Stuttg). 2017 Aug;67(8):447-450. doi: 10.1055/s-0042-121491. Epub 2017 May 30.

PMID:
28561241
8.

Paediatric Medicines: Regulatory and Scientific Issues.

Daousani C, Karalis VD.

Drug Res (Stuttg). 2017 Jul;67(7):377-384. doi: 10.1055/s-0043-109788. Epub 2017 May 18. Review.

PMID:
28521373
9.

Pharmacokinetic analysis of inhaled salmeterol in asthma patients: Evidence from two dry powder inhalers.

Soulele K, Macheras P, Karalis V.

Biopharm Drug Dispos. 2017 Oct;38(7):407-419. doi: 10.1002/bdd.2077. Epub 2017 Jul 12.

PMID:
28374512
10.
11.

A non-binary biopharmaceutical classification of drugs: the ABΓ system.

Macheras P, Karalis V.

Int J Pharm. 2014 Apr 10;464(1-2):85-90. doi: 10.1016/j.ijpharm.2014.01.022. Epub 2014 Jan 21.

PMID:
24456673
12.

On the statistical model of the two-stage designs in bioequivalence assessment.

Karalis V, Macheras P.

J Pharm Pharmacol. 2014 Jan;66(1):48-52. doi: 10.1111/jphp.12164. Epub 2013 Oct 31.

PMID:
24175961
13.

Generic products of antiepileptic drugs: a perspective on bioequivalence, bioavailability, and formulation switches using Monte Carlo simulations.

Karalis V, Macheras P, Bialer M.

CNS Drugs. 2014 Jan;28(1):69-77. doi: 10.1007/s40263-013-0112-8.

PMID:
24092569
14.

Quantitative assessment of the switchability of generic products.

Karalis V, Bialer M, Macheras P.

Eur J Pharm Sci. 2013 Nov 20;50(3-4):476-83. doi: 10.1016/j.ejps.2013.08.023. Epub 2013 Aug 24.

PMID:
23981332
15.

The role of the upper sample size limit in two-stage bioequivalence designs.

Karalis V.

Int J Pharm. 2013 Nov 1;456(1):87-94. doi: 10.1016/j.ijpharm.2013.08.013. Epub 2013 Aug 14.

PMID:
23954235
16.

Keeping a critical eye on the science and the regulation of oral drug absorption: a review.

Macheras P, Karalis V, Valsami G.

J Pharm Sci. 2013 Sep;102(9):3018-36. doi: 10.1002/jps.23534. Epub 2013 Apr 9. Review.

PMID:
23568812
17.

An insight into the properties of a two-stage design in bioequivalence studies.

Karalis V, Macheras P.

Pharm Res. 2013 Jul;30(7):1824-35. doi: 10.1007/s11095-013-1026-3. Epub 2013 Apr 9.

PMID:
23568524
18.

Exploring the relationships between scaled bioequivalence limits and within-subject variability.

Symillides M, Karalis V, Macheras P.

J Pharm Sci. 2013 Jan;102(1):296-301. doi: 10.1002/jps.23365. Epub 2012 Nov 15.

PMID:
23160971
19.

Current regulatory approaches of bioequivalence testing.

Karalis V, Macheras P.

Expert Opin Drug Metab Toxicol. 2012 Aug;8(8):929-42. doi: 10.1517/17425255.2012.690394. Epub 2012 Jun 11. Review.

PMID:
22681436
20.

Safety and pharmacokinetics of oseltamivir for prophylaxis of neonates exposed to influenza H1N1.

Maltezou HC, Drakoulis N, Siahanidou T, Karalis V, Zervaki E, Dotsikas Y, Loukas YL, Theodoridou M.

Pediatr Infect Dis J. 2012 May;31(5):527-9. doi: 10.1097/INF.0b013e3182472f28.

PMID:
22209917

Supplemental Content

Loading ...
Support Center